LMP01 FACTS
Some LMP01´s facts that will redefine the landscape of glioblastoma treatment.
After two decades without significant breakthroughs in the treatment of this deadly disease, LMP01 emerges as a beacon of hope in the battle against glioblastoma.
This pioneering therapeutic, borne from relentless research represents a significant leap forward in our quest to conquer even the most aggressive forms of this disease including its Wild-Type and Mutant IDH1 variants.
Distinguished by its mechanisms of action, LMP01 sets its sights on pivotal pathways implicated in glioblastoma progression, first halting tumor growth and subsequently reducing tumor size. LMP01 shows very promising potential to surmount the intricate challenges posed by glioblastoma, including its invasive tendencies and resistance to conventional therapies.
Built upon a foundation of profound insight into the molecular intricacies driving glioblastoma, LMP01 represents a seismic shift in therapeutic paradigms.
LMP01 stands poised to redefine the landscape of glioblastoma treatment, offering hope of multi-year survival and enhanced quality of life for those affected by this relentless brain cancer.
Some LMP01´s facts that will redefine the landscape of glioblastoma treatment.
New combination of two small molecules - attacks two brain cancer targets.
One product FDA approved for different indication, the other is GRAS.
Novel administration route avoids systemic toxicity and strengthens patent position.
Improvement slow / significant positive impact on OS and QOL.
Less expensive than other treatments
May be effective for other forms of brain cancer.
Our mission and base strategy
